BRIEF—Sun Pharma to launch generic Glumetza generic

Indian generics giant Sun Pharma has announced the launch of a new generic equivalent to the diabetes drug Glumetza (metformin hydrochloride) in the USA.

According to analytics company IQVIA, the market size for Glumetza is almost half a billion dollars per year. Sun had originally received the regulatory nod in 2016, when the estimated market size was $1.2 billion.

Both Lupin and Teva have a head start in the sales race over Sun, having launched their own generic Glumetza equivalents in 2016 and 2017 respectively.